A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Learn more about Protagenic Therapeutics Inc’s (PTIX) stock grades for Growth, Momentum and Quality and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Dylan Dease
| Share Statistics | PTIX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1.9 | $288.9 | 1% |
|
| Shares Out (Mil) | 1.8 | 54.0 | 7% |
|
| Institutional Ownership | 47.9% | 93.1% | 21% |
|
| Float (Mil) | 1.7 | 41.4 | 5% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 51 | 480 | 29% |
|
| Price Change (52-week) |
(67.1%) | 59.9% | 10% |
|
| Growth | PTIX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | PTIX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | $6 | ($43) | 43% |
|
| EPS (TTM) | $2.942 | ($1.500) | 78% |
|
| Operating Cash Flow (TTM) (Mil) | ($2) | ($31) | 29% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | na | $190 | na |
|
| Valuation | PTIX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.11 | 2.84 | 25% |
|
| P/E | 0.4 | 20.0 | 0% |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PTIX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | 117.7% | (47.7%) | 100% |
|
| ROE | (485.4%) | (55.0%) | 1% |
|
| Liabilities to Assets | 38.4% | 29.6% | 29% |
|
| F-Score | 3 | 3 | 18% |
|
Protagenic Therapeutics, Inc. did not pass any screens on 9/2/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
